Cris Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 26-06-2024
- Paid Up Capital ₹ 1.24 Cr
as on 26-06-2024
- Company Age 32 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 26-06-2024
- Satisfied Charges ₹ 8.13 Cr
as on 26-06-2024
- Revenue 1.15%
(FY 2023)
- Profit -5.04%
(FY 2023)
- Ebitda 9.25%
(FY 2023)
- Net Worth 16.18%
(FY 2023)
- Total Assets 2.13%
(FY 2023)
About Cris Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.24 Cr.
The company currently has active open charges totaling ₹3.00 Cr. The company has closed loans amounting to ₹8.13 Cr, as per Ministry of Corporate Affairs (MCA) records.
Suwa Jat, Poonam Taparia, and Kailash Melana serve as directors at the Company.
- CIN/LLPIN
U24139RJ1992PLC034757
- Company No.
034757
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
01 Sep 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cris Pharma (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suwa Jat  | Director | 25-Jul-2011 | Current |
| Poonam Taparia | Whole-Time Director | 25-Aug-1997 | Current |
| Kailash Melana | Director | 20-Mar-2005 | Current |
Financial Performance of Cris Pharma (India).
Cris Pharma (India) Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.15% increase. The company also saw a slight decrease in profitability, with a 5.04% decrease in profit. The company's net worth Soared by an impressive increase of 16.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cris Pharma (India)?
In 2023, Cris Pharma (India) had a promoter holding of 81.69% and a public holding of 18.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 25 Feb 2021 | ₹5.00 M | Open |
Others Creation Date: 16 Nov 2017 | ₹2.50 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Jul 2014 | ₹2.40 Cr | Satisfied |
How Many Employees Work at Cris Pharma (India)?
Cris Pharma (India) has a workforce of 161 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cris Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cris Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
